Abstract: Human conglutinin, polyclonal, and monoclonal antibodies raised against human conglutinin, and their uses in therapy and diagnosis are described.Human conglutinin was obtained from human plasma by affinity chromatography with anti-bovine conglutinin antibody, has a relative molecular weight of 330 and 40 K unreduced and 66 K reduced as measured by SDS-PAGE, shows calcium-dependent and sugar inhibitable binding to complement-reacted immune complexes and zymosan, and immunological cross-reaction with anti-bovine conglutinin antibody.
Abstract: The invention relates to a process for preparing immunogenic complexes in which an amphiphatic antigenic protein or peptide in dissolved or solubilized form is contacted with a solution containing a detergent, a sterol, and a glycoside comprising hydrophobic and hydrophilic regions, in at least the critical micelle forming concentration, the detergent is removed, and the immunogenic complex formed is purified. Optionally, the solution with which the antigenic protein or peptide is contacted also contains a phospholipid, preferably phosphatidylethanolamine. The preferred sterol is cholesterol, and preferred glycosides are saponins, espeically Quil A.The immunogenic complex is useful as a vaccine. Its immunogenic power is higher than that of corresponding micelles formed by aggregation of the antigens, and is also higher than that of the antigens incorporated in liposomes.
Type:
Grant
Filed:
January 14, 1987
Date of Patent:
February 13, 1990
Assignee:
De Staat der Nederlanden Vertegenwoordigd door de Minister van Welzion, Volksgezondheid en Cultuur
Inventors:
Petra De Vries, Antonius L. van Wezel, deceased, Eduard C. Beuvery
Abstract: To maintain an almost unchanged plasma-protein profile in a patient subsequent to plasma exchange, the plasma-exchange medium contains the most essential human serum proteins, except for the coagulation factors, at a concentration of 75 g/l.
Abstract: High-yielding hybridoma cell lines which secrete monoclonal antibodies capable of binding to tumor cells of one or more types, but not normal cells can be obtained more readily by fusing myeloma cells with antibody-forming cells isolated from an animal immunized with tumor antigens, which has previously been made immunological tolerant to normal cell antigens, comprising the total antigens, or at least a proportion of the total antigens, of the normal cells corresponding to the tumor cells chosen as the source of immunizing antigens.
Abstract: Monoclonal antibodies being capable of reacting with human squamous cell lung carcinoma, lung adenocarcinoma and large cell lung carcinoma, and non-reactive with human small cell lung carcinoma and normal human lung cells, and recognizing glycoproteins as antigens. Hybridomas having the characteristics of cell line SLC-454 secrete such antibodies. Method of diagnosing human lung cancer and method of therapeutic treatment are described.
Type:
Grant
Filed:
July 6, 1987
Date of Patent:
January 9, 1990
Assignee:
Kyowa Hakko Kogyo Co., Ltd.
Inventors:
Hajime Yoshida, Nobuo Hanai, Kenya Shitara
Abstract: Hybridomas which produce monoclonal antibodies specific to an abnormal branched determinant of a synthetic glycolipid antigen and methods of use of the monoclonal antibodies.
Abstract: Described is composition of matter and methods useful for the indentification of blood group antigens. Additionally a kit which can be used to identify and quantify a large number of blood group antigens is disclosed. The composition of matter and the methods can be used to identify antigens on red blood cells, as well as, on tissue samples.
Type:
Grant
Filed:
July 9, 1987
Date of Patent:
November 21, 1989
Assignee:
Baylor College of Medicine
Inventors:
Richard A. Hull, Sheila I. Hull, Bogdan Nowicki
Abstract: An analysis of LEU3, a leucine-specific regulatory locus encoding a factor for control of RNA levels of a group of leucine-specific genes, is provided.DNA sequence analysis of a clone of LEU3 shows that it contains an open reading frame of 886 amino acids. There are three regions of particular interest: a cluster of acidic amino acids that are located in the C-terminal half of the coding region, a region with a repeated cysteine motif, and a region of partial homology with MATalpha2. A LEU3-dependent DNA binding activity is demonstrated to interact with homologous portions of the 5'-region of LEU1 and LEU2.
Abstract: IgE binding factors (IgE-bfs) with IgE suppressor (IgE-SF) activity obtainable from human colostrum in an enriched form, a method for the prevention and/or the treatment of allergy by administering the IgE-bfs and pharmaceutical compositions comprising said IgE-bfs.
Abstract: Pasteurization of immunoglobulin solutions to inactivate viruses without significantly altering the IgG molecules or their physiological activities is obtained with minimal aggregation in the absence of any stabilizer by heating this solution to mildly-elevated temperatures at low ionic strength and mildly acid pH values.
Type:
Grant
Filed:
November 24, 1987
Date of Patent:
July 18, 1989
Assignee:
Connaught Laboratories Limited
Inventors:
Anthony A. Magnin, Po-Shing Wah, Paul Dennis
Abstract: A biologically active composition extracted from thymus tissue, capable of inducing immature bone marrow cells to differentiate into competent suppressor T-cells.
Abstract: A new immunotherapeutic method of treating lower respiratory tract infection caused by respiratory syncytial virus (RSV) is disclosed. The method employs topical application of RSV antibodies into the lower respiratory tract. The new treatment modality is more effective and rapid than the conventional therapy.
Type:
Grant
Filed:
May 28, 1987
Date of Patent:
January 24, 1989
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Gregory Prince, Robert Chanock, Val G. Hemming